Priority CRISPR

PTAB Upholds Broad Institute's Priority in CRISPR-Cas9 Patent Dispute with University of California

The U.S. Patent Trial and Appeal Board (PTAB) has reaffirmed its 2022 decision that the Broad Institute, MIT, and Harvard hold priority for the invention of CRISPR-Cas9 gene editing applications in eukaryotic cells. This ruling follows a remand from the U.S. Court of Appeals for the Federal Circuit, which requested re…